scholarly journals Parametric Modelling of Migraine Day Frequency In Migraine Prevention: A Case Study Of Erenumab Clinical Trial Data

2017 ◽  
Vol 20 (9) ◽  
pp. A733
Author(s):  
JK Porter ◽  
GL Di Tanna ◽  
G Villa ◽  
A Brennan ◽  
S Palmer ◽  
...  
2008 ◽  
Vol 27 (11) ◽  
pp. 1801-1813 ◽  
Author(s):  
Joel B. Greenhouse ◽  
Eloise E. Kaizar ◽  
Kelly Kelleher ◽  
Howard Seltman ◽  
William Gardner

2012 ◽  
Vol 40 (2) ◽  
pp. 391-393
Author(s):  
Elie Donath Mark ◽  
J. Eisenberg

There is a concern that physicians/researchers are inappropriately profiting (by buying or selling stock) from information derived from advance copies of high-impact clinical trial data distributed by medical conferences or journals. Despite these concerns, it has never been systematically evaluated, and little is known about the degree to which it exists. This is largely due to difficulties associated with directly verifying whether or not such activities have taken place and, furthermore, many medical conferences/journals today have taken the necessary actions to guard against this. One medical association in particular, the American Society of Clinical Oncology (ASCO responsible for conducting the largest annual oncology-related medical conference), only began responding to such concerns several years ago. Their actions during that time serve as a compelling case study, with wide-ranging ramifications, and provide the unique opportunity to delve into this phenomenon.Up until 2008, ASCO selectively and discreetly distributed abstracts from all forthcoming presentations (at the ASCO Conference) to ASCO members two weeks prior to it becoming publicly accessible during the conference.


Sign in / Sign up

Export Citation Format

Share Document